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Abstract: Children with special health care needs (CSHCN) use relatively high quantities of healthcare
resources and have overall higher morbidity than the general pediatric population. Embedding
clinical pharmacists into the Patient-Centered Medical Home (PCMH) to provide comprehensive
medication management (CMM) through collaborative practice agreements (CPAs) for children,
especially for CSHCN, can improve outcomes, enhance the experience of care for families, and reduce
the cost of care. Potential network infrastructures for collaborative practice focused on CSHCN
populations, common language and terminology for CMM, and clinical pharmacist workforce
estimates are provided. Applying the results from the CMM in Primary Care grant, this paper outlines
the following: (1) setting up collaborative practices for CMM between clinical pharmacists and
pediatricians (primary care pediatricians and sub-specialties, such as pediatric clinical pharmacology);
(2) proposing various models, organizational structures, design requirements, and shared electronic
health record (EHR) needs; and (3) outlining consistent documentation of CMM by clinical pharmacists
in CSHCN populations.
Keywords: clinical pharmacist; pediatrician; clinical pharmacology; pharmacotherapy;
comprehensive medication management; pediatric medicines; special needs; collaboration; children;
care networks
1. Introduction and Statement of Need
U.S. children’s hospitals and health systems have identified a lack of a standard definition for
children with special health care needs (CSHCN). A lack of consensus may diminish the effectiveness of
improvement projects designed to address social determinants of health in children, especially CSHCN
and/or those with medical complexity (CMC) [1]. According to the Maternal and Child Health Bureau
of the Health Resources and Services Administration (HRSA), CSHCN is defined as children and youth
that “have or who are at risk for chronic physical, developmental, behavioral, or emotional conditions,
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and who also require health and related services of a type or amount beyond that by children generally.”
Nearly 20% (or 17 million) of children under the age of 18 have at least one special need [2]. CMC, a
sub-population of approximately 3 million, require the highest level of services and support due to their
care intensity and the breadth of pediatric sub-specialists required [3]. This CMC sub-population is
growing in terms of resource utilization, and requires policy and programmatic interventions that differ
from broader CSHCN groups. Systems of care for CMC should be informed through evidence-based
solutions to the ongoing challenges of caring for CMC with better sub-population definitions, especially
in the areas of community care and outcomes measurement [4–7]. Qualitative themes have emerged in
defining the population health of CMC, including health optimization and outcome measurement, and
the importance of family and social determinants [8]. For community primary care providers (PCPs),
patient and drug regimen characteristics such as polypharmacy, multi-organ system involvement, and
rare/unfamiliar diagnoses often negatively affect care. In addition, caregivers with high needs, time
constraints during visits, and challenges with care coordination were also frequently cited as impairing
good clinical outcomes [9]. Key challenges are reported to be development of a consensus method to
identify CMC, promotion of high-quality research, navigation of health care reform, and measures to
promote professional identity and workforce development [7].
Within the evolving programs and systems of care for CSHCN and CMC, there is a need for
better medication management processes and systems to aid in the coordination and quality of care
received, especially during transitions of care and in the home environment [7,9–12]. While pediatric
patients and their drug therapy needs, in general, are very different from adults, there are structures
and processes of care that can be universally applied regardless of patient population. Among these
are comprehensive medication management (CMM) within the structure of collaborative practice
agreements (CPAs) between clinical pharmacists and physicians, such as those which have been
successfully developed and implemented in adult primary care practices, associations, and health
systems [13].
The overall purpose of this concept paper is to address the need for and creation of a
pharmacotherapy collaborative practice network through CPAs for CMM in children and youth
populations. In addition, this paper outlines the following: (1) organizing a collaborative practice for
CMM between a clinical pharmacist and a pediatrician (primary care pediatricians and sub-specialties,
such as pediatric clinical pharmacology); (2) describing and proposing various models, organizational
structures, design requirements, and shared electronic health record (EHR) needs; and (3) outlining
consistent documentation of CMM by clinical pharmacists in CSHCN populations.
2. Children with Special Health Care Needs and Medical Complexity (CSHCN and CMC)
2.1. Current Models of Care Delivery
There are three current models of care for CMC: (1) primary care-centered models; (2) consultative-
or co-management-centered models; and (3) episode-based models. While these models have
been evaluated favorably, they lack generalizability since standardized outcomes and population
definitions for CMC are lacking. Collaboration among patients, families, providers, payers, and policy
makers is required to identify gaps in care and build high reliability guidelines [6]. CMC models
need to encompass comorbid neurodevelopmental conditions that frequently accompany outpatient
encounters [14]. For example, CMC with upper and lower respiratory tract and gastrointestinal
conditions are being treated through multidisciplinary aerodigestive centers at tertiary care centers,
and integration of a general pediatrician can promote a whole-person Patient Centered Medical Home
(PCMH) [15]. One report described an overarching theme “unsung heroes, flying blind” that illustrate
aspects of the parents’ experience in caring for CSHCN and CMC. The enormous burden of care can
decrease the parents’ ability to provide care, and impact the parents’ health, family functioning and
the sick child’s potential health outcomes [16]. Comprehensive care oversight may improve care
coordination but not health status for parents of CMC [17].
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2.2. Population Health Aspects of the Patient-Centered Medical Home (PCMH)
In Figure 1, Kindig has provided a conceptual framework for understanding population health
(PH), which can be applied to CSHCN and focus on both determinants of care and outcomes. Population
health is defined as the “the health outcomes of a group of individuals, including the distribution of
such outcomes within the group” [18].
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Population health management (PHM) approaches to improve cost and quality have included an
operating model which incorporates: “(1) a multi-layered, interprofessional infrastructure; (2) data
dashboards to guide continuous quality improvement; (3) revamped provider payments; (4) consumer
spending accounts; and (5) incentive alignment for shared savings with practices.” One mechanism for
improving the organization and delivery of health care to populations, in general, and for CSHCN-CMC,
in particular, is the Patient Centered Medical Home (PCMH) [19]. PCMH is not a place, but a model
for primary care delivery encompassing comprehensive care, patient centeredness, coordinated care,
accessible services, and quality and safety [20]. Primary care practices face any barriers to providing
PCMH care to patients with complex needs. Reported barriers include the organization’s structure,
lack of resources such as staff, space, and technology, and communication between health care team
members [21]. Innovative programs that focus on patients with high resource utilization, place case
managers in primary care practices, allow flexibility in matching staff to the needs of each practice, and
help primary care clinicians manage CMC alongside regular patients i prove care for CMC. More
support is needed for smaller primary care practices to become effective PCMHs for CMC. Increased
reimbursement is necessary for practices to have the resources to serve CMC effectively and to support
programs that collaborate with primary care practices. Further research is required to delineate delivery
models that will succeed in different types of communities [22]. Data from the 2016 National Survey of
Children’s Health (N = 50 212) indicated that 43.2% of CSHCN and 50% of otherwise healthy children
have access to a medical home. Attainment of the Medical Home Composite Measure, as measured by
the National Survey of Children’s Health, is defined by five subcomponents including a usual source
of care, having a personal physician or nurse, receiving needed referrals, receiving coordinated care,
and receiving family-centered care varied significantly by sociodemographic characteristics among
both CSHCN and non-CSHCN, as did attainment rates for each of the five subcomponents [23].
CSHCN with broad functional impairment (physical, cognitive, and mental health) demonstrated
the highest emergency department (ED) utilization, highest odds of hospitalization, and lowest odds of
a having a medical home [24]. CSHCN with functional limitations may have poorer health status and
more complex health care needs, and more often experience a variety of health issues due to inadequate
insurance, increased impact of health conditions on the family, and higher medical costs [25]. A third
of families of CSHCN, predominantly with children from racial/ethnic minority backgrounds, those
in poverty, and those with complex emotional/ behavioral or developmental needs and functional
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limitations, are reported to encounter difficulties, delays, or frustrations in obtaining health and related
services [26,27]. Unmet needs in CMC may be double that of those without medical complexity [28].
PCMHs exist often in primary care practices, since these pediatricians are more comfortable than
specialist pediatricians in providing a medical home for a child with chronic medical or developmental
conditions [29,30].
In one study, CMC had a mean of 19 annual outpatient visits (USD $616) and one in four
had inpatient visits ($3308), with other significant cost drivers including home health ($2957) and
prescription medications ($2182). The main reasons for CMC visits were for mental health [31].
Compared to families without CSHCN, those with CMC have, on average, lower satisfaction with
health care. Total spending increases for children with chronic conditions might be due to an increase
in the number of recipients with the most complex chronic conditions, not increased per member per
month payment to primary care providers [31]. The presence of multiple extracardiac co-morbidities is
often associated with higher resource utilization following the index cardiac surgical procedure [32].
As qualifiers for special needs status among American Indian/Alaska Native (AIAN) children, the use
of or need for prescription medication was the most frequent, and significantly greater disease burden
among AIAN CSHCN suggests that care must be taken to ensure an appropriate level of coordinated
care in a medical home to ameliorate the severity and complexity of their conditions [11].
2.3. Youth with Special Health Care Needs (YSHCN)
Youth with Special Heath Care Needs (YSHCN), aged 12–17 years, represent a unique
sub-population of CSHCN, and a majority may have three or more comorbid conditions. Efforts
for this sub-population should focus on strengthening coordinated systems of care that optimally
meet the needs of YSHCN so they may thrive in their families and communities [10]. Only one-third
of YSHCN had adequate transition to adult care preparation (care coordination, shared decision
making, and family-centered care), and the majority that lack it are male adolescents with medical
complexity [33]. One recent example of a hospital-based transition preparation infrastructure included
five core objectives: “(1) facilitating medical transition with a focus on structure and processes;
(2) assessing current transition policy/practice at baseline; (3) communicating the complexity and
necessity of transition planning; (4) mobilizing adult providers to champion transition planning for
YSHCN; and (5) identifying methods to analyze transition program building activities” [34]. PCMH
can encompass such strategies in developing programs to transition YSHCN to adult care.
2.4. Behavioral Health
Neurodevelopmental conditions affect ~15% of US children, and the prevalence and complexity
of these conditions are increasing. The workforce struggles to meet current service demands, with
long waiting times for appointments, increased complexity, and high volumes of non-reimbursed care.
Sustaining the subspecialty will require strategies to maintain and expand the workforce, improve
clinical efficiency, and prevent burnout [35]. Older children and those living in poorer households were
more likely to have an unmet need for behavioral healthcare services among CSHCN with CMC. The
prevalence of unmet mental healthcare needs among both groups increased during 2005–2010 [36]. An
important component of behavioral health PCMH is shared decision making (SDM), which engages
the patient or caregiver in medical decisions based on the values, preferences and treatment goals of the
patient or caregiver. For younger children, parents are usually involved in SDM. However, with older
children and adolescents, attention deficit/hyperactivity disorder (ADHD) and/or autism spectrum
disorder (ASD), most of the SDM processes involve the parent [37]. While future strategies should be
implemented to incorporate the child or adolescent as appropriate, challenges due to cognitive abilities
in children with CSHCN may hamper effective SDM [38].
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2.5. Quality/Continuity of Care/Care Coordination
Care coordination is defined by the Agency for Healthcare Research and Quality (AHRQ) as
“optimally organizing patient care and information-sharing activities” [39]. Coordination is an
important aspect of high quality, patient-centered care. It improves safety, effectiveness, and efficiency
of health care provided. Measures of coordination processes must be robust for generating evidence
about its outcomes, analyzing existing practices, developing quality improvement activities, and
supporting targeted payment initiatives. Continuity of care holds promise as a quality measure
for CMC because of its association with lower ED utilization and more frequent receipt of care
coordination [40]. Recently, the Family Experience with Coordination of Care assessed the quality of
coordination as reported by the caregiver [41]. The Post-Acute Acuity Rating for Children, intended to
reflect medical severity based on age, reason for admission, diagnoses, dependence in activities of daily
living, and technology reliance for children admitted to post-acute care rehabilitation hospitals, has
been found to be a comparable measurement of medical complexity for pediatric outpatient care [42].
Use of the CSHCN Screener, a five-item scale that identifies needs, helps to target CSHCN who need
coordination, access to specialized and community-based services, and enhanced SDM. However,
lack of integration into EHR limits the use of the CSHCN Screener in many clinical settings [43,44].
A greater percentage of CMC may use social work services than non-CMC, with over eight times
more hours of services provided per child per year [45]. Overall family-centered care planning and
delivery for CMC is optimized when the medical and social needs of the child are integrated [46].
High performing community-based complex care clinics integrated with a tertiary care center may
lead to a decrease in total health care system costs per patient per month, fewer inpatient days in
the tertiary care center, decreased out of pocket expenses, and durable improvements in social and
emotional quality of life for children [47]. Strategies to improve coordination have included scheduling
additional time with patients and caregivers, summative care plans, and facilitated synchronous and
asynchronous communication with specialists [9].
3. Comprehensive Medication Management (CMM)
The American College of Clinical Pharmacy (ACCP) recently developed a common language
document for delivering CMM [48]. Vital to communicating both internally and external to the
profession, and especially to patients, the document contains the operational definitions that assure a
standardized patient care process within each essential pharmacist function, as outlined below:
1. Collect and analyze information about the patient and drug therapy history;
2. Assess the information and formulate a medication therapy problem (MTPs) list;
3. Develop the care plan in collaboration with healthcare team and patient/caregiver;
4. Implement the care plan; and
5. Follow up and monitor to optimize the care plan and resolve MTPs.
Applying implementation science principles into practice in a stepwise fashion, especially
creating “bite-sized objectives” through SMART goals (Specific, Measurable, Actionable, Realistic, and
Time-bound) and enlisting physician champions, has been shown to produce positive outcomes for
integrating clinical pharmacists in adult primary care practices [49]. Clinical pharmacists practicing
under collaborative practice agreements (CPAs) or through other privileging processes are well
positioned to improve care coordination through provision of CMM. As shown in Figure 2, CMM is
founded on three core components: (1) a shared philosophy of practice; (2) the patient care process;
and (3) practice management systems.
In 2011, 90% of all Medicaid-insured CMC required medications that averaged US $1677 per
child [50]. CMC represents about 3% of CSHCN, and CMC parents report significantly more unmet
needs for prescription medications and care coordination compared to non-CMC parents. These may
be associated with unmet care coordination and greater medical complexity. Pharmacists are rarely
part of the CSHCN care coordination model. With the complexity of and numerous transitions of care
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for CSHCN-CMC, pharmacists can be responsible to advocate for the unfulfilled needs for prescription
medications as care delivery models for these children evolve [12].
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The American College of Clinical Pharmacy (ACCP) believes that clinical pharmacists engaged
in direct patient care activities such as CMM should be board certified (i.e., residency-trained or
otherwise board eligible) and have established valid CPAs or have been formally granted clinical
privileges [51–55].
CMM is a primary method for medication optimization, a result of merging implementation
science expertise with lessons learned from the “CMM in Primary Care” grant [48,53]. Six essential
domains common to other health disciplines comprise CMM: “direct patient care, pharmacotherapy
knowledge, systems-based care and population health, communication, professionalism, and
continuing professional development.” These competencies are specifically designed to identify
the unique clinical pharmacy expertise needed to provide CMM from a patient-centered, team-based
perspective” [54,55]. Face-to-face CMM has resulted in increased rates of medication adherence [56].
Since 1995, the Department of Veterans Affairs has allowed Clinical Pharmacy Specialists (CPS) an
expanded scope of practice with independent prescribing privileges [57].
Physicians have identified enhanced clinical outcomes, access to drug knowledge, and creation of
a multidisciplinary model for learners as the top benefits of working with clinical pharmacists, but
note limited reimbursement and billing difficulties as primary challenges [58]. Access to primary care
health records can help community pharmacists build an efficient and effective CMM practice [59].
4. Collaborative Practice and Agreements (CPA)
In 2012, the American Pharmacists Association Foundation convened a roundtable consortium
that generated seven recommendations for advancing pharmacists’ patient care services and CPAs
which included:
• “use of consistent terminology;
• provider control over collaborative practice details;
• infrastructure that embeds pharmacists’ patient care services and CPAs into care;
• use of electronic health records and technology in patient care services;
• relationships among the health care team that are strong, trusting, and mutually beneficial;
• incentive alignments based on meaningful process and outcome measures; and
• redesign of health professionals’ practice acts, education curriculums, and operational policies”
(see Figure 3) [60,61].
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effectively achieves intended outcomes [74].
CMM focuses on optimizing the patient’s entire drug therapy whereas disease management is
centered on one disease state, such as diabetes, heart failure, asthma, and hypertension. In the case
of CPAs involving children, CMM could be initiated in patients with two or more active chronic
diagnoses that are managed with medications [75,76], for immunizations [77], during transitions
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of care from hospital to home [12,78], or when children with neurodevelopmental issues become
adolescents [79–82].
Many jurisdictions in North America allow for pharmacists and physicians to determine the
extent to which a patient is involved in a CPA, including informed consent and written consent with
opt-out provisions. It is important to specify in detail the expectations and responsibilities for care. If
guidelines or practice parameters are available, it is suggested that these documents form the clinical
basis of the CPA. Specific definitions of drug therapy management have included adjusting a drug
regimen, adjusting drug strength, frequency or route of administration, administering drugs, ordering
pertinent laboratory tests, monitoring vital signs, and educating and training patients related to home
management of drug therapy. A toolkit for creating CPAs for CMM in other countries is described in
another paper of this Special Issue.
5. Network Design Requirements and Electronic Health Record (EHR) Needs
5.1. Overview
The speed of change from volume-based to value-based payment in health care varies widely.
Focusing on the family’s well-being goals, successful community-based PH models have leveraged
strong payer-provider partnerships have the potential to reduce healthcare costs and maintaining or
improving care quality [83,84]. Figure 4 illustrates one PH structure where pharmacotherapy may be
involved for CSHCN-CMC at several nodes in the care process. When considering the constitution
of a pharmacy-based network, it is important to understand how pharmacotherapy assessment,
monitoring, and follow up can be situated within the core capabilities of behavioral health, complex
disease management, telehealth, and care management. Moreover, how well these core components
articulate with adjacent capabilities, such as primary care networks and pediatric to adult transitions,
can improve care coordination for overall medication management and positive patient outcomes.
Examples that utilize such PHM models can occur in various settings. Pharmacists have provided
patient care using CPAs for diabetes, hypertension, and hyperlipidemia in PCMH clinics. Legal
agreements were developed for sharing data and for accessing state-wide EHR at a large chain
community pharmacy in one US state for over five years. No statistically significant differences were
seen in blood glucose, lipids, or blood pressure outcomes for patients seen by PCMH versus community
pharmacists, indicating that, when EHR is available, CMM can be conducted without regard to
location [85]. A discharge clinic approach achieved a significant decrease in 30-day readmission
rate compared with national benchmark data. The medical group’s estimated cost of readmissions
was US $7,156,800, and 30-day all-cause readmission rate was 12.3%. Use of a post discharge clinic
resulted in an estimated savings of $689,199 and 9.63%, a total estimated net savings of $335,199 [86].
An ambulatory care pharmacy-based transitions-of-care (TOC) program for 830 managed Medicaid
patients reduced total healthcare costs at 180 days after discharge by an average of $2139 or an estimated
plan savings of nearly $1.8 million [87].
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5.2. Potential Models and Accompanying Logistical Needs
To provide for the overarching structure, potential network models are evolving. There are
pharmacy-based, pediatrician office-based, telehealth (call center) based and hybrid, multi-level models.
Within the pharmacy-based network, there are several existing clinically-integrated community focused
networks wherein pediatric patients may receive CMM. An example of this structure is the National
Association of Community Pharmacy—Community Pharmacy Enhanced Services Network (CPESN);
within CPESN, all member pharmacies are capable of providing the following medication management
services, including reconciliation, synchronization, vaccinations, and CMM. Additional services
at select pharmacies include collection of vital signs, POC testing, administration of long-acting
injections, and compounding sterile and non-sterile preparations. CPESN support solutions include
quality improvement, quality assurance and practice transformation guided by CPESN clinicians and
data analysts.
Some pharmacy supplier-based networks with internal clinical infrastructure can support
collaborative practices (Professional Compounding Centers of America (PCCA; https://www.pccarx.
com/); International Academy of Compounding Pharmacists (IACP; https://www.iacprx.org/); and
Cardinal Health; https://www.outcomesmtm.com/pharmacy/medication-therapy-management/).
The infrastructure of these networks often is comprised of in-house clinical and scientific expertise
that assists community pharmacists in collaboration with patients and pediatricians. For example,
within Cardinal Health’s OutcomesMTM® company, patients are connected through the Personal
PharmacistTM Network with face-to-face and telepharmacy components to leverage pharmacists
with unique access to prescribers, some of which are embedded in physician practices. Alternatively,
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standards-setting organizations and professional societies that have the pharmacotherapy of children as
their central focus might organize collaborative and electronic networks exclusively designed to improve
drug therapy outcomes in pediatrics as a population. In other words, pharmacotherapy and medication
management systems for children need to include more than federal governmental approvals and
pediatric society efforts; the complexities in CSHCN require increased orchestrated transdisciplinary
collaboration designed to foster innovation through practice-based research and innovation.
While the number of pharmacists practicing CMM within pediatrician offices is unknown, several
health system-based clinics have formed collaborations internally and with large community chain
pharmacy organizations and companies to facilitate collaborative care [88,89]. In these collaborations,
ambulatory clinical pharmacists are included on inter-professional outpatient teams to optimize
medication use. Outpatient pharmacists conducted medication reviews while ambulatory clinical
pharmacists focused on CMM. Specialty groups, such as the Childhood Arthritis and Rheumatology
Research Alliance in North America and others focused on outpatient chronic care management, afford
another potential network arrangement for pharmacist-pediatrician collaboration [90,91]. In a pilot
study, collaboration between a community pharmacy and local pediatric primary care centers targeted
asthma, a major chronic disease in children [92].
CMM can be provided via telehealth applications [93]. Primary care outcomes in a telehealth-based
chronic disease management program that includes clinical pharmacists for diabetes, hyperlipidemia,
hypertension control and tobacco cessation can be achieved in targeted patients [94]. Multidisciplinary
therapeutic class management in pediatric behavioral health completed peer-to-peer consultations via
telepharmacy for medication changes, dose reductions, and elimination of polypharmacy within or
across behavioral health medication classes [79].
6. Consistent Documentation of CMM by Pharmacists in CSHCN-CMC Populations
6.1. Current Gaps in Pediatric Medication Management
A joint opinion of the ACCP Pediatrics Practice and Research Network and the Pediatric Pharmacy
Advocacy Group outlined four strategies to expand the quality and capacity of pediatric clinical
pharmacist care, including elevating minimum entry-to-practice expectations, standardizing education,
expanding the number of pediatric clinical pharmacists, and addressing research development of
pediatric clinical pharmacists and clinical scientists. The ultimate goal was to improve access for all
pediatric patients, including CSHCN [95]. In addition, there are many gaps in the current system
for medication management that directly affect pediatric patients and their families. These gaps can
be divided into four major areas of attention: (1) lack of standardized formulations designed for
children; (2) lack of information exchange and standard nomenclature to describe products used in
children; (3) lack of collaboration for CMM between pediatricians and clinical pharmacists at the
point of care; and (4) lack of effective feedback for understanding the impact of pharmacotherapy on
patient outcomes.
Mass-produced drug products and formulations suitable for children, especially those below
the age of 6 years, are lacking. Useful active pharmaceutical ingredients (APIs) with finished oral
liquid dosage forms available either adapted from other countries or registered in North America
and beyond has been suggested [96,97]. To optimize the effectiveness and safety of “off-label” use
of compounded pharmacotherapy through complete transmission of electronic prescriptions across
the continuum of care, a pediatric compounded non-sterile products repository (pCNSP) has been
proposed [98]. Existing federal and corporate database structures for medical language could be
employed to incorporate pCNSPs to facilitate complete transmission of electronically identifiable and
standardized extemporaneous formulations. The lack of inclusion also stymies a uniform approach
to CMM for pediatric patients, as these products do not appear on the patients’ medication records
accurately [99].
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Because medication use in children continues to be associated with an unacceptably high rate
of adverse events, morbidity, and death, a distinct medicines-use system designed explicitly for
them has been proposed [100]. A rise in the prevalence in chronic diseases such as diabetes, obesity,
and inflammatory bowel diseases, is causing an increased utilization of medications that can lead
to more medication errors or adverse drug events. For example, obesity now affects almost 20%
of U.S. children and adolescents. Morbid obesity now affects 6% of all U.S. youth [101]. CMM
in this rapidly-rising sub-population should consider for potential for drug-induced weight gain
where pharmacists are embedded in the inter-professional ambulatory or community healthcare
delivery for pediatric patients. Pediatric polypharmacy can be addressed through CMM services,
chart reviews, and other medication-related activities [102]. Pediatric pharmacy has recently been
credentialed as a board-certified pharmacy specialty through the auspices of the Board of Pharmacy
Specialties (https://www.bpsweb.org) [103]. Any new network that develops for the management
of pharmacotherapy in children would be bolstered with the inclusion of board-certified pediatric
pharmacy specialists (BCPPS) located within health system or pediatrician group practices or within
internal support staffs of community, chain, and/or supplier organizations.
6.2. Potential Network Architectures, Configuration, and Designs
There are two essential components of any network designed to provide patient care or services:
(1) human factors related to the proximity among providers of care delivery; and (2) informatics
infrastructure related to health data gathering, storage, and routing/transmission. Any design must
assure that the network is stable, secure, and sustainable over time. While there are many architectures,
configurations, and designs that could be employed to network CMM in pediatric pharmacotherapy,
it is important that these structures be designed intentionally with the end user, children and their
families, in mind. In addition, there needs to be a simulation aspect to any network so that changes in
system requirements, inputs, and outputs can be tested prior to activation in a production environment.
There are two common paradigms that facilitate the distribution of information: (1) hub and
spoke architectures; and (2) multicasting architectures [104]. It has been shown that providers need
to connect visually and on an interpersonal basis. Applied to pediatric providers involved in this
network, their proximity to each other, whether face-to-face, within the same local community, or
remote / distance, is an important factor in trust development and network sustainment.
Hub and spoke designs have been applied to health care systems involving providers and
informatics, academic settings, and research endeavors (see Figure 5). These involve a central unit
(hub or message broker) that receives transmissions from an initiator and distributes messages to
listener objects. In this structure, there may be one hub object per channel or a single master object to
connect with all channels, facilitate data sharing, and SDM. In this design, the transmitter (care initiator)
sends data (clinical observations and documentation, including eRx) to the network hub. The hub is
comprised of listener objects (authorized care manager devices) assigned to receive information from
the transmitter. The listener interprets the message and sends a new message to a terminal recipient.
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Multicast involves passing synchronous messages within one or more channels that signal end
users when information is available in the channel (see Figure 6). Copies are created and routed
automatically to network segments that contain members of the listener object group.
In either case, network architectures for both practitioners and data can be situated in tandem
or separately. For example, the Surescripts Network Alliance™ began as a functionality to facilitate
electronic prescribing, and has evolved a repository for medication histories and prior authorization
functionality [105]. Surescripts connects payers and pharmacy benefit managers, pharmacies, inpatient
and outpatient prescribing and dispensing software, and hospitals and care providers [106]. A
similar platform can be derived for a separate and distinct prescription-processing and medication
management system that provides access to authorized practitioners caring for the needs of children
and their families.
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6.3. Estimating the Number of Clinical Pharmacists Needed to Care for CSHCN-CMC
Although population estimates of the number of pharmacists needed in society is based on
prescrip ion fulfillment, data fro the Bureau of Labor Statistics have shown repeatedly that there are
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about one-third as many pharmacists as physicians; in 2016, there were 713,800 physicians and surgeons
practicing in the US [107]. According to the American Academy of Pediatrics (AAP), there were about
92,000 physician-pediatricians and over 28,000 medical and surgical sub-specialists, or about 120,000
pediatricians [108]. The AAP also believes that there is a current shortage of sub-specialty-trained
pediatricians, and the distribution of generalists and primary care in rural and other underserved
areas is inadequate [19]. Since estimates of CSHCN and sub-groups is elusive presently, a reasonable
projection of the direct care needs of CSHCN-CMC for clinical pharmacists providing CMM in the
U.S. ranges from a 1:3 to a 1:5 ratio to pediatricians, including sub-specialists. In the U.S., this would
translate conservatively into between 24,000 and 40,000 clinical pharmacists needed, bearing in mind
that the ratio for patients with complex chronic needs may be lower than for primary care, unless
primary care is the PCMH. Moreover, the number of clinical pharmacists needed is affected by the
extent to which sterile and non-sterile compounding and prescription fulfillment activities are part of
the practice in addition to CMM. However, it is apparent from the preceding discussion that clinical
pharmacists practicing CMM for CSHCN can improve access to safe and effective pharmacotherapies.
The professions need to collaborate at local and national levels as a way of practicing in order to achieve
measurable outcomes.
7. Summary and Recommendations
This report contains forward-thinking statements designed to stimulate mindfulness and concerted
action for improving healthcare delivery and medication management in children. Medication use
is a major aspect of CSHCN, and mismanagement is fraught with ambiguity, error, and morbidity.
Including board-certified pediatric clinical pharmacists providing CMM, either on-site (such as in
a PCMH) or remotely, in evolving population health care networks for children has been proposed
in an effort to create a dialogue that improves the likelihood for individual and population health
optimization. As a medication optimization strategy, CMM has a common language and terminology
for operationally defining direct patient care rendered by clinical pharmacists. Learnings from CMM
application in adult primary care may afford better understanding of the potential for pharmacist
collaborative care across the pediatric continuum.
The evolution of a network of clinical pharmacists providing CMM for CSHCN may be best
facilitated by insertion of pediatrics-trained and board-certified faculty from schools and colleges of
pharmacy into ambulatory clinics of pediatric hospitals and health systems. Alternatively, existing
pharmacist provider networks, such as the Community Pharmacy Enhanced Network and the Personal
Pharmacist Network, may expand to include CMM for children based on a set of shared collaborative
practice objectives. These two approaches may be integrated to form a regional network that improves
access both to board-certified pediatric pharmacy specialists and to quality medications. CPAs
involving children’s CMM could be initiated in patients with two or more active chronic diagnoses that
are managed with medications, for immunizations, or during transitions of care from hospital to home.
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Abbreviations
AAP American Academy of Pediatricians
ACCP American College of Clinical Pharmacy
APhA American Pharmacists Association
BCPPS Board-certified pediatric pharmacy specialists
CMC children with medical complexity
CMM comprehensive medication management
CPA collaborative practice agreement
CSHCN children with special health care needs
EHR electronic health record
PCMH patient centered medical home
PCP community primary care provider
pCNSP pediatric compounded nonsterile preparation
PH population health
PHM population health management
SDM shared decision making
TOC transitions of care
YSHCN youth with special health care needs
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